Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Thomas Zeyen"'
Autor:
Frank A. Giordano, Julian P. Layer, Sonia Leonardelli, Lea L. Friker, Roberta Turiello, Dillon Corvino, Thomas Zeyen, Christina Schaub, Wolf Müller, Elena Sperk, Leonard Christopher Schmeel, Katharina Sahm, Christoph Oster, Sied Kebir, Peter Hambsch, Torsten Pietsch, Sotirios Bisdas, Michael Platten, Martin Glas, Clemens Seidel, Ulrich Herrlinger, Michael Hölzel
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II trial combining RT and the CXCL12-n
Externí odkaz:
https://doaj.org/article/a461b70c215e421cabb2b9a14f5dfb4b
Autor:
Marco M. E. Vogel, Arthur Wagner, Jens Gempt, Harald Krenzlin, Thomas Zeyen, Richard Drexler, Martin Voss, Charlotte Nettekoven, Tammam Abboud, Dorothee Mielke, Veit Rohde, Marco Timmer, Roland Goldbrunner, Joachim P. Steinbach, Lasse Dührsen, Manfred Westphal, Ulrich Herrlinger, Florian Ringel, Bernhard Meyer, Stephanie E. Combs
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has changed the clinical day-to-day practice. The aim of this study was to evaluate the impact of the pandemic on patients with high-grade glioma (HGG) as well as to deriv
Externí odkaz:
https://doaj.org/article/e8cd6733dae945f5a79bd251874ac446
Autor:
Julian P. Layer, Katharina Layer, Gustavo R. Sarria, Fred Röhner, Cas S. Dejonckheere, Lea L. Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen, Mümtaz Köksal, Frederic Carsten Schmeel, Niklas Schäfer, Jennifer Landsberg, Michael Hölzel, Ulrich Herrlinger, Matthias Schneider, Frank A. Giordano, Leonard Christopher Schmeel
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1300-1313 (2023)
Purpose: To determine the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM), either as a definitive or adjuvant treatment. Methods: We assessed clinical data of patients receiving five fractions of
Externí odkaz:
https://doaj.org/article/14acb167281c4e949dff21e05e773afc
Autor:
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, Dieter H. Heiland, Michael C. Burger, Joachim P. Steinbach, Peter Hau, Ghazaleh Tabatabai, Martin Glas, Uwe Schlegel, Oliver Grauer, Dietmar Krex, Oliver Schnell, Roland Goldbrunner, Michael Sabel, Niklas Thon, Daniel Delev, Hans Clusmann, Clemens Seidel, Erdem Güresir, Matthias Schmid, Patrick Schuss, Frank A. Giordano, Alexander Radbruch, Albert Becker, Johannes Weller, Christina Schaub, Hartmut Vatter, Judith Schilling, Frank Winkler, Ulrich Herrlinger, Matthias Schneider
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-16 (2022)
Abstract Background Glioblastoma is the most frequent and malignant primary brain tumor. Even in the subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and favorable response to first-line therapy, survival after relaps
Externí odkaz:
https://doaj.org/article/a07626c82ec8444ab56a35322801927a
Autor:
Richard Drexler, Jennifer Göttsche, Thomas Sauvigny, Ulrich Schüller, Robin Khatri, Fabian Hausmann, Sonja Hänzelmann, Tobias B Huber, Stefan Bonn, Dieter H Heiland, Daniel Delev, Varun Venkataramani, Frank Winkler, Johannes Weller, Thomas Zeyen, Ulrich Herrlinger, Jens Gempt, Franz L Ricklefs, Lasse Dührsen
Publikováno v:
Neuro-Oncology. 25:1006-1008
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7043f666e32ee0c994a0047e894ba443
https://doi.org/10.1093/neuonc/noad014
https://doi.org/10.1093/neuonc/noad014
Autor:
Johannes Weller, Niklas Schäfer, Christina Schaub, Anna-Laura Potthoff, Joachim P. Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Clemens Seidel, Dietmar Krex, Roland Goldbrunner, Torsten Pietsch, Theophilos Tzaridis, Thomas Zeyen, Valeri Borger, Erdem Güresir, Hartmut Vatter, Ulrich Herrlinger, Matthias Schneider
Publikováno v:
Journal of Neuro-Oncology. 159:95-101
Purpose The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1abe1daeebe881cbe5ecaed27b0cb4e
https://doi.org/10.1007/s11060-022-04046-z
https://doi.org/10.1007/s11060-022-04046-z
Autor:
Thomas Zeyen, Daniel Paech, Johannes Weller, Niklas Schäfer, Theophilos Tzaridis, Cathrina Duffy, Louisa Nitsch, Matthias Schneider, Joachim Steinbach, Peter Hau, Uwe Schlegel, Clemens Seidel, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Pia Zeiner, Ghazaleh Tabatabai, Norbert Galldiks, Walter Stummer, Elke Hattingen, Martin Glas, Alexander Radbruch, Ulrich Herrlinger, Christina Schaub
Publikováno v:
Neuro-Oncology. 24:vii169-vii170
INTRODUCTION In the randomized CeTeG/NOA-09 trial, combined CCNU/TMZ was superior to TMZ therapy regarding overall survival (OS) in newly diagnosed patients with MGMT-methylated glioblastoma. Using modified RANO criteria, however, progression-free su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d41cd8d6987819245c1445d12e4c121e
https://doi.org/10.1093/neuonc/noac209.650
https://doi.org/10.1093/neuonc/noac209.650
Autor:
Thomas Zeyen, Arno Reich, Tobias Goldmann, Alexander Slowik, Eren Arik, Pardes Habib, Michael Huber, Jennifer Jung, Ole Heinisch, Marco Prinz, Shahin Habib, Jörg B. Schulz
Publikováno v:
Translational stroke research 13, 462–482 (2022). doi:10.1007/s12975-021-00948-8
Inflammasomes are known to contribute to brain damage after acute ischemic stroke (AIS). TAK1 is predominantly expressed in microglial cells and can regulate the NLRP3 inflammasome, but its impact on other inflammasomes including NLRC4 and AIM2 after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70d1e00e7b03e20272709be850d9975
https://juser.fz-juelich.de/record/905217
https://juser.fz-juelich.de/record/905217
Autor:
Johannes Weller, Thomas Zeyen, Uwe Schlegel, Lazaros Lazaridis, Jan-Michael Werner, Julia Onken, Pia Zeiner, Richard Drexler, Peter Hau, Clemens Seidel, Lucia Grosse, Hans Clusmann, Michael Sabel, Florian Ringel, Josef Pichler, Oliver Grauer, Thomas Hundsberger, Oliver Schnell, Maximilian J Mair, Martin Uhl, Friederike Schmidt-Graf, Martin Glas, Norbert Galldiks, Meike Unteroberdörster, Joachim Steinbach, Franz Ricklefs, Mirjam Renovanz, Daniel Ivanov Delev, Merih O Turgut, Oliver R Flesch, Debora Cipriani, Matthias Preusser, Sied Kebir, Martin Misch, Roland Goldbrunner, Manfred Westphal, Ghazaleh Tabatabai, Niklas Schäfer, Matthias Schneider, Hartmut Vatter, Frank Giordano, Christina Schaub, Ulrich Herrlinger
Publikováno v:
Neuro-Oncology. 24:vii71-vii71
INTRODUCTION The CeTeG/NOA-09 trial demonstrated superior median overall survival (mOS, 48.1 months) in MGMT-methylated glioblastoma treated with lomustine/temozolomide compared to temozolomide. We retrospectively analyzed an off-study cohort of pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0784bda4e49c6cb6c96ccf07fa59b5
https://doi.org/10.1093/neuonc/noac209.274
https://doi.org/10.1093/neuonc/noac209.274
Autor:
Clemens Seidel, Katharina Sahm, Thomas Zeyen, Sotirios Bisdas, Frank A. Giordano, Elena Sperk, Sied Kebir, Julian P Layer, Ulrich Herrlinger, Sonia Leonardelli, Martin Glas, Lea Friker, Torsten Pietsch, Christina Schaub, Peter Hambsch, Michael Hölzel
Publikováno v:
Neuro Oncol
BACKGROUND Preclinical studies showed that CXCL12-mediated influx of highly angiogenic monocytes/macrophages is a key driver of tumor re-vascularization and re-growth after radiotherapy (RT) of glioblastoma (GBM). We report findings from a phase I/II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e295cf828fb360634306c6dddeec1c